CRT Licensing Portfolio

Including small molecules, biological therapeutics, biomarkers, enabling technology and research tools.

Small molecules

• Inhibitors of LIMK1 and LIMK2 – hit-to-lead/lead optimisation
• Chk1 inhibitor programme – in vivo proof-of-principle
• Chk2 inhibitor programme – lead optimisation
• Novel inhibitors of Aurora Kinase – lead optimisation
• Inhibitors of MDM2-p53 protein-protein interaction – hit-to-lead/lead optimisation
• CYP26 inhibitor programme – hit-to-lead

For further information about the opportunities in the small molecules portfolio, please visit the website.

Biological therapeutics

• DNA Fusion Vaccines – Clinical Phase I/II
• Novel Tumour Endothelial Markers – Target Validation
• PASD1 – A Novel Cancer Antigen – in vivo Proof-of-Principle
• Therapeutic HPV Vaccine – Clinical Phase II

For further information about the opportunities in the biological therapeutics portfolio, please visit the website.

Biomarkers

• MCM Proteins – Diagnostic Markers for Lung Cancer – Validation
• SNAIL – A Prognostic Marker for Epithelial Cancers – Discovery

For further information about the opportunities in the biomarkers portfolio, please visit the website.

Enabling technology

• CyMap – A novel imaging device with multiple applications
• Transposon mediated genomic DNA integration
• Induronate scalable chemistry methods
• Novel marker of early ES cell differentiation
• Endothelial tissue-specific and inductible cre transgenic mice
• Cytochrome b5 KO mouse model for study of drug metabolism
• Cytochrome b5 KO mouse model for study of steosis

For further information about the opportunities in the enabling technology portfolio, please visit the website.

Research tools

CRT has been successfully commercialising research reagents created in academic institutes for over 20 years. Our impressive portfolio exceeds 600 monoclonal and polyclonal antibodies as well as cell lines and transgenic mice models.

To view the research tools portfolio, please visit the website.